Inborn errors of metabolism and other monogenic disorders represent a diverse and rapidly expanding category of rare diseases for which precision therapies are increasingly available. Next-generation sequencing has accelerated diagnosis and uncovered previously unrecognised genetic heterogeneity. Newborn screening expansion, enzyme replacement, substrate reduction, and gene therapy are reshaping care pathways across this category.
Loading articles...
